The technology from Opyl uses artificial intelligence to anticipate a COVID-19 treatment, vaccine, diagnostic or device’s chances of success in a study.
A leader from the clinical trial technology firm shares how direct data capture and other solutions can address the unique needs of such complex studies.
Merck and Seattle Genetics have announced two strategic oncology collaborations: one to develop Seattle Genetics’ antibody-drug conjugate ladiratuzumab vedotin worldwide; and another to accelerate the global reach of Tukysa (tucatinib).
The company’s Medidata Detect centralized trial monitoring solution is designed to improve management of data quality, site monitoring and patient safety.
Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
